google-site-verification: googlec7193c3de77668c9.html

FDA clears blood test for Alzheimer disease

[

FDA clears blood test for Alzheimer disease

The U.S. Food and Drug Administration has cleared the PrecivityAD2 test for adults 40 and older presenting with signs or symptoms of cognitive impairment and undergoing evaluation for Alzheimer’s disease or other forms of cognitive decline.

PrecivityAD2 uses high-resolution mass spectrometry to provide quantitative measurements of protein biomarkers. The test is intended to be used in conjunction with a clinical assessment and is not intended as a screening or standalone diagnostic test.

The clearance is based on a trial of 1,142 adults presenting with signs or symptoms of cognitive decline, which showed the test had comparable accuracy to cerebrospinal fluid tests and brain scans for detecting amyloid plaques across the spectrum of cognitive impairment. PrecivityAD2 showed a 97.6% positive predictive value (rule-in) for a positive result and a 93.1% negative predictive value (rule-out) for a negative result, based on established reference methods of amyloid positron emission tomography visual read or cerebrospinal fluid biomarker testing. Overall, a likely positive test result occurred in 17.3% of participants, with a positive predictive value of 77.3%.

“We believe the PrecivityAD2 test will play a vital health system role in the years ahead to help streamline and simplify the complex diagnostic pathway that many patients face when dealing with serious memory concerns,” Joel Braunstein, co-founder, CEO and president of C2N Diagnostics, said in a statement.

More information

More Information

Key medical concepts

Alzheimer’s DiseaseNeuritic Plaque

Clinical categories

NeurologyLaboratory medicine

Who’s behind this story?


Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news.

Full profile →


Andrew Zinin

Andrew Zinin

Master’s in physics with research experience. Long-time science news enthusiast. Plays key role in Science X’s editorial success.

Full profile →

Advertisements

© 2026 HealthDay. All rights reserved.

Citation:
FDA clears blood test for Alzheimer disease (2026, September 3)
retrieved 3 September 2026
from https://medicalxpress.com/news/2026-09-fda-blood-alzheimer-disease.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.




Source link

See also  Lung cancer screening with computed tomography finds coronary artery disease in 83% of cases

Check Also

Social media 'spiral' found after sister's death

A woman whose 13-year-old sister took her own life says the “spiral that she was …

New study lifts the lid on why no/lo alcohol beer drinkers feel out of pocket

[ Price of products available and products purchased for regular-strength and no/lo beer, cider, wine, …

New GP and wellbeing hub in Newhavan ‘a major milestone’

The council says the plan is to create an environment which can offer healthcare, wellbeing …

Leave a Reply

Available for Amazon Prime